Cobimetinib
- PDF / 169,511 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 56 Downloads / 130 Views
1 S
Retinopathy: case report A 65-year-old woman developed retinopathy during treatment with cobimetinib for breast cancer [route and dosage not stated]. The woman, who had stage IV breast cancer metastasised to liver and lungs presented with new onset of multiple green spots in both the eyes. The spots were stationery and not associated with photophobia or pain. Her visual acuity was 20/20. A dilated fundus examination demonstrated multifocal, hypopigmented, cream-colored spots scattered throughout the posterior pole of both the eyes. The spots were hyper-auto fluorescent on fundus area and they were localised to the sub-retinal space. During investigations, it was noted that, two weeks prior to the current presentation, she was started on cobimetinib for breast cancer as a part of a clinical trial. In clinical investigations, laboratory tests ruled out the possibility of infectious cause. The noted changes were discussed and a diagnosis of cobimetinib associated retinopathy was made. Despite retinopathy, the woman’s cobimetinib was continued considering the aggressive breast cancer. Following 2 weeks, even after continuation of cobimetinib, her retinal symptoms had resolved and the visual acuity returned to the baseline. Patel SN, et al. Sudden Onset of Multiple Green Spots in the Eyes of a Woman With Breast Cancer. JAMA Ophthalmology 138: 412-413, No. 4, 2020. Available from: URL: 803520814 http://doi.org/10.1001/jamaophthalmol.2019.5288
0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Dec 2020 No. 1834
